vs
Side-by-side financial comparison of ATLANTIC AMERICAN CORP (AAME) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $53.8M, roughly 1.7× ATLANTIC AMERICAN CORP). Vericel Corp runs the higher net margin — 25.0% vs 1.1%, a 23.9% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 20.8%). Vericel Corp produced more free cash flow last quarter ($12.8M vs $6.6M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 7.2%).
The Atlantic Telegraph Company was a company formed on 6 November 1856 to undertake and exploit a commercial telegraph cable across the Atlantic Ocean, the first such telecommunications link.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
AAME vs VCEL — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $53.8M | $92.9M |
| Net Profit | $577.0K | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | 1.4% | 24.1% |
| Net Margin | 1.1% | 25.0% |
| Revenue YoY | 20.8% | 23.3% |
| Net Profit YoY | 128.9% | 17.3% |
| EPS (diluted) | $0.02 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $92.9M | ||
| Q3 25 | $53.8M | $67.5M | ||
| Q2 25 | $55.3M | $63.2M | ||
| Q1 25 | $50.1M | $52.6M | ||
| Q4 24 | $49.0M | $75.4M | ||
| Q3 24 | $44.5M | $57.9M | ||
| Q2 24 | $47.7M | $52.7M | ||
| Q1 24 | $47.0M | $51.3M |
| Q4 25 | — | $23.2M | ||
| Q3 25 | $577.0K | $5.1M | ||
| Q2 25 | $3.3M | $-553.0K | ||
| Q1 25 | $802.0K | $-11.2M | ||
| Q4 24 | $412.0K | $19.8M | ||
| Q3 24 | $-2.0M | $-901.0K | ||
| Q2 24 | $-684.0K | $-4.7M | ||
| Q1 24 | $-2.0M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | — | 24.1% | ||
| Q3 25 | 1.4% | 5.1% | ||
| Q2 25 | 7.6% | -3.2% | ||
| Q1 25 | 2.1% | -24.3% | ||
| Q4 24 | 1.1% | 24.5% | ||
| Q3 24 | -5.5% | -4.3% | ||
| Q2 24 | -1.8% | -11.5% | ||
| Q1 24 | -5.3% | -10.7% |
| Q4 25 | — | 25.0% | ||
| Q3 25 | 1.1% | 7.5% | ||
| Q2 25 | 6.0% | -0.9% | ||
| Q1 25 | 1.6% | -21.4% | ||
| Q4 24 | 0.8% | 26.3% | ||
| Q3 24 | -4.5% | -1.6% | ||
| Q2 24 | -1.4% | -8.9% | ||
| Q1 24 | -4.3% | -7.5% |
| Q4 25 | — | $0.46 | ||
| Q3 25 | $0.02 | $0.10 | ||
| Q2 25 | $0.15 | $-0.01 | ||
| Q1 25 | $0.03 | $-0.23 | ||
| Q4 24 | $0.01 | $0.40 | ||
| Q3 24 | $-0.10 | $-0.02 | ||
| Q2 24 | $-0.04 | $-0.10 | ||
| Q1 24 | $-0.10 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $34.4M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $109.5M | $354.6M |
| Total Assets | $430.9M | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | $34.4M | $135.4M | ||
| Q2 25 | $46.4M | $116.9M | ||
| Q1 25 | $35.9M | $112.9M | ||
| Q4 24 | $35.6M | $116.2M | ||
| Q3 24 | $23.0M | $101.7M | ||
| Q2 24 | $21.2M | $102.5M | ||
| Q1 24 | $21.2M | $110.6M |
| Q4 25 | — | $354.6M | ||
| Q3 25 | $109.5M | $321.9M | ||
| Q2 25 | $106.2M | $306.8M | ||
| Q1 25 | $102.4M | $295.5M | ||
| Q4 24 | $99.6M | $292.0M | ||
| Q3 24 | $105.8M | $257.5M | ||
| Q2 24 | $100.7M | $243.0M | ||
| Q1 24 | $102.8M | $233.9M |
| Q4 25 | — | $488.0M | ||
| Q3 25 | $430.9M | $453.3M | ||
| Q2 25 | $429.3M | $435.6M | ||
| Q1 25 | $388.4M | $424.6M | ||
| Q4 24 | $393.4M | $432.7M | ||
| Q3 24 | $387.0M | $390.4M | ||
| Q2 24 | $386.0M | $376.8M | ||
| Q1 24 | $365.8M | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $6.6M | $15.0M |
| Free Cash FlowOCF − Capex | $6.6M | $12.8M |
| FCF MarginFCF / Revenue | 12.3% | 13.8% |
| Capex IntensityCapex / Revenue | 0.1% | 2.4% |
| Cash ConversionOCF / Net Profit | 11.51× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $19.3M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $15.0M | ||
| Q3 25 | $6.6M | $22.1M | ||
| Q2 25 | $9.3M | $8.2M | ||
| Q1 25 | $-722.0K | $6.6M | ||
| Q4 24 | $4.8M | $22.2M | ||
| Q3 24 | $90.0K | $10.2M | ||
| Q2 24 | $416.0K | $18.5M | ||
| Q1 24 | $-5.3M | $7.2M |
| Q4 25 | — | $12.8M | ||
| Q3 25 | $6.6M | $19.5M | ||
| Q2 25 | $9.1M | $81.0K | ||
| Q1 25 | $-986.0K | $-7.6M | ||
| Q4 24 | $4.6M | $8.5M | ||
| Q3 24 | $58.0K | $-9.2M | ||
| Q2 24 | $361.0K | $1.8M | ||
| Q1 24 | $-5.4M | $-6.8M |
| Q4 25 | — | 13.8% | ||
| Q3 25 | 12.3% | 28.8% | ||
| Q2 25 | 16.5% | 0.1% | ||
| Q1 25 | -2.0% | -14.5% | ||
| Q4 24 | 9.3% | 11.2% | ||
| Q3 24 | 0.1% | -15.9% | ||
| Q2 24 | 0.8% | 3.4% | ||
| Q1 24 | -11.4% | -13.3% |
| Q4 25 | — | 2.4% | ||
| Q3 25 | 0.1% | 3.9% | ||
| Q2 25 | 0.3% | 12.9% | ||
| Q1 25 | 0.5% | 27.0% | ||
| Q4 24 | 0.5% | 18.3% | ||
| Q3 24 | 0.1% | 33.5% | ||
| Q2 24 | 0.1% | 31.8% | ||
| Q1 24 | 0.1% | 27.3% |
| Q4 25 | — | 0.65× | ||
| Q3 25 | 11.51× | 4.35× | ||
| Q2 25 | 2.80× | — | ||
| Q1 25 | -0.90× | — | ||
| Q4 24 | 11.65× | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AAME
| Bankers Fidelity | $30.0M | 56% |
| American Southern | $23.7M | 44% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
